Abivax SA

ABVX

Healthcare|Biotechnology|France

$139.90

-0.87 (-0.62%)

Tangible Book

$5.81

Earnings Power

$7.00

Upcoming Data Readouts (3)

Sep 2026

Est. completion

P1Healthy

Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation

Dec 2026

Est. completion

P2Moderately to Severely Active Crohn Disease

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Mar 2028

Est. completion

P2Ulcerative Colitis

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Trials past primary completion date but still active — data readout may be imminent.

Apr 2026

ABTECT - Maintenance